Log in

NYSE:AGE - AgeX Therapeutics Stock Price, Forecast & News

+0.05 (+3.70 %)
(As of 02/17/2020 06:00 AM ET)
Today's Range
Now: $1.40
50-Day Range
MA: $1.66
52-Week Range
Now: $1.40
Volume167,493 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of therapeutics for age-related degenerative diseases in the United Stated. The company is developing AGEX-BAT1 and AGEX-VASC1, which are cell-based approaches in the preclinical stage of development to correct metabolic imbalances in aging; and to restore vascular support in ischemic tissues. It is also involved in the development of AGEX-iTR1547, a drug-based formulation in preclinical development for restoring regenerative potential in various aged tissues afflicted with degenerative diseases. In addition, the company develops Renelon, a first-generation tissue regeneration product designed to promote scarless tissue repair. Further, it markets genomic interpretation algorithms; and Cytiva, including pluripotent stem cell derived heart muscle cells used in screening drugs for efficacy and safety. The company was founded in 2017 and is based in Alameda, California. AgeX Therapeutics, Inc.(AMEX:AGE) operates independently of BioTime, Inc. as of November 28, 2018.

Industry, Sector and Symbol

Industry N/A



Sales & Book Value

Annual SalesN/A



Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable

Receive AGE News and Ratings via Email

Sign-up to receive the latest news and ratings for AGE and its competitors with MarketBeat's FREE daily newsletter.

AgeX Therapeutics (NYSE:AGE) Frequently Asked Questions

What is AgeX Therapeutics' stock symbol?

AgeX Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGE."

When is AgeX Therapeutics' next earnings date?

AgeX Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for AgeX Therapeutics.

Has AgeX Therapeutics been receiving favorable news coverage?

Headlines about AGE stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. AgeX Therapeutics earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for AgeX Therapeutics.

What other stocks do shareholders of AgeX Therapeutics own?

Who are AgeX Therapeutics' key executives?

AgeX Therapeutics' management team includes the folowing people:
  • Mr. Alfred D. Kingsley, Exec. Chairman (Age 75)
  • Dr. Michael D. West, Pres, CEO & Director (Age 65)
  • Mr. Russell L. Skibsted, Chief Financial Officer (Age 59)
  • Mr. Nafees Naseer Malik, Chief Operating Officer
  • Dr. Aubrey D. N. J. de Grey BA, MA,Ph.D., Vice-Pres of New Technology Discovery

Who are AgeX Therapeutics' major shareholders?

AgeX Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (0.70%), Defender Capital LLC. (0.37%), Panagora Asset Management Inc. (0.21%), UBS Group AG (0.09%) and Barclays PLC (0.06%). View Institutional Ownership Trends for AgeX Therapeutics.

Which major investors are selling AgeX Therapeutics stock?

AGE stock was sold by a variety of institutional investors in the last quarter, including Defender Capital LLC. and Panagora Asset Management Inc.. View Insider Buying and Selling for AgeX Therapeutics.

Which major investors are buying AgeX Therapeutics stock?

AGE stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG, State Street Corp and Barclays PLC. View Insider Buying and Selling for AgeX Therapeutics.

How do I buy shares of AgeX Therapeutics?

Shares of AGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AgeX Therapeutics' stock price today?

One share of AGE stock can currently be purchased for approximately $1.40.

MarketBeat Community Rating for AgeX Therapeutics (NYSE AGE)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  43 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  94
MarketBeat's community ratings are surveys of what our community members think about AgeX Therapeutics and other stocks. Vote "Outperform" if you believe AGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Featured Article: Bid-Ask Spread

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel